February 2010 in “Journal of The American Academy of Dermatology” Lower nitric oxide and higher fibrinogen found in hirsute women; impaired sexual function in 22.6% of hair loss patients, linked to psoriasis severity.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
47 citations,
June 2017 in “Journal of dermatology” New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
44 citations,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
39 citations,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
29 citations,
June 2013 in “Journal of the Saudi Society of Dermatology & Dermatologic Surgery” Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
25 citations,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
22 citations,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
20 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
19 citations,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
17 citations,
April 2020 in “Dermatology and Therapy” The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
14 citations,
June 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
12 citations,
September 2020 in “Journal of cosmetic dermatology” Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.
12 citations,
June 2017 in “Dermatologic therapy” Higher concentrations of dithranol can help regrow hair in severe alopecia areata.
12 citations,
January 2011 in “Photodermatology, photoimmunology & photomedicine” This therapy effectively treats resistant alopecia areata with minimal side effects.
11 citations,
May 2021 in “Journal of The American Academy of Dermatology” COVID-19 doesn't make alopecia areata worse.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.